In this article, we will discuss Durvalumab (Geriatric Use-2). So, let’s get started.
Of the 476 patients treated with Durvalumab in the PACIFIC study, 45% were 65 years or older, while 7.6% were 75 years or older. No overall differences in safety or effectiveness were observed between patients 65 years or older and younger patients. The PACIFIC study did not include sufficient numbers of patients aged 75 years and over to determine whether they respond differently from younger patients.